Clinical trials
Chemoradiotherapy clinical trials
Below are recruiting chemoradiotherapy clinical trials, each written for real people, not researchers. We’re tracking 236 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07689851RecruitingPhase 2
Chemoradiotherapy plus an immunotherapy for advanced gastric cancer
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
Shenzhen, GuangdongAges 18–75 - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06687876RecruitingPhase 2
Metformin before chemoradiation for esophageal cancer
This trial tests if taking metformin (a diabetes pill) before standard chemoradiation can make esophageal cancer respond better. You take metformin for 2 weeks before starting standard treatment, and doctors will check your tumor with two endoscopies to see how it changes.
AmsterdamAges 18 years+ - NCT06697938Recruiting
Chemo plus radiation vs. chemo alone for locally advanced breast cancer
This trial compares two treatments for locally advanced breast cancer: chemotherapy before surgery plus radiation, versus chemotherapy before surgery alone. The goal is to see which approach works better for this specific type of cancer.
Chengdu, SichuanAges 18–70 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06727617RecruitingPhase 2
Serplulimab with chemoradiation for high-risk cervical cancer
This trial tests adding an immunotherapy drug (serplulimab) to standard chemoradiation after cervical cancer surgery. It is for patients with at least two high-risk features, like lymph node spread or deep invasion, to see if it helps prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06730308RecruitingPhase 2
Steroids with chemoradiation for thymoma that can't be removed
This trial tests if adding a steroid (methylprednisolone) to standard chemotherapy and radiation helps people with thymoma that cannot be fully removed by surgery or has come back. The goal is to see if this combination works better at controlling the disease.
Guanzhou, GuangdongAges 18–75 - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT06755866Recruiting
Predicting chemo-radiation response with improved MRI for esophageal cancer
This trial uses a special MRI technique to see if it can predict how well esophageal cancer responds to chemo-radiotherapy before surgery. It may help doctors choose the best treatment plan for you.
Kunming, YunnanAges 18–80 - NCT06792786Recruiting
Study of Chemo-Immunotherapy and Radiation for Esophageal Cancer with Blood Monitoring
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
Jinhua, ZhejiangAges 18–75 - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT06812728RecruitingPhase 2
Chemo and radiation before surgery for advanced rectal cancer
This trial tests giving a strong chemotherapy combination (FOLFIRINOX) followed by radiation before surgery for locally advanced rectal cancer. If you have stage 3 or high-risk stage 2 rectal cancer that has not spread, this approach may shrink the tumor and improve outcomes.
Shibīn al Kawm, MenoufiaAges 18–70 - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+ - NCT06831981Recruiting
Heat therapy with chemo and radiation for rectal cancer
This trial tests if adding heat therapy (hyperthermia) to standard chemotherapy and radiation helps treat rectal cancer that has high-risk features. Heat therapy is thought to make cancer cells more sensitive to treatment.
Tübingen, Baden-WurttembergAges 18 years+ - NCT06843889RecruitingPhase 2
Toripalimab with chemoradiation before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
Guangzhou, Baiyun DistrictAges 18–75 - NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT06851247RecruitingPhase 2
Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18–65 - NCT06869239Recruiting
Predicting response to PD-L1 inhibitor after chemoradiotherapy for limited-stage small cell lung cancer
This study uses a blood test to see if it can predict how well the PD-L1 inhibitor (an immunotherapy drug) works after standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to find better ways to match treatment to patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06885814RecruitingPhase 2
Adebrelimab with chemoradiation for advanced esophageal cancer
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06908070RecruitingPhase 4
Chemoradiation, surgery, then durvalumab for stage 3 lung cancer
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
AmsterdamAges 18 years+ - NCT06912074RecruitingPhase 2
Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Guangzhou, GuangdongAges 18–80 - NCT06947668Recruiting
Biomarker study for people who can't take cisplatin chemo
This study looks at immune system markers in patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. The goal is to understand how well a different chemotherapy drug (docetaxel) combined with radiation works in these patients.
Erlangen, BavariaAges 18 years+ - NCT06949098RecruitingPhase 2
Local tumor removal plus chemo-radiation for early low rectal cancer
This trial tests whether removing just the tumor locally, followed by chemotherapy and radiation, is effective for early-stage (T1-2 N0) rectal cancers located low or very low in the rectum. It may help you keep your anal opening and avoid major surgery that requires a permanent colostomy bag.
Shijiazhuang, HebeiAges 18–75 - NCT06952101Recruiting
Personalized treatment for rectal cancer to save the organ
This trial tests a personalized, step-by-step approach for rectal cancer that aims to avoid surgery and preserve the rectum. It is for patients whose tumor has shrunk significantly after chemoradiation, or who have early-stage high-risk cancer removed during a scope procedure.
Candiolo, TurinAges 18 years+
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chemoradiotherapy?
- Yes. Clin2 currently lists 236 recruiting chemoradiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chemoradiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chemoradiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.